LIND vs VKTX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LIND and VKTX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LIND and VKTX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Lindblad Expeditions Holdings is a New York based expedition travel company that runs small-ship voyages to places like Antarctica, the Arctic, the Galapagos and Alaska, most of them co-branded with National Geographic under a long-running partnership. It reports two segments. The Lindblad segment is the ship business, which produced ~$129.2 million of the ~$199.2 million in second-quarter 2026 tour revenue. Land Experiences is a group of guided tour companies (Natural Habitat Adventures, Off the Beaten Path, DuVine Cycling + Adventure, Classic Journeys and Wineland-Thomson Adventures) that contributed the other ~$70.0 million. In September 2026 it agreed to buy 60% of White Desert, which flies guests into the Antarctic interior, and the aviation brand Echo Charlie for ~$61 million in cash, which management called the largest transaction in the company's history.

Full LIND guide

Viking Therapeutics (VKTX) is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. Its highest-profile program is VK2735, a dual GLP-1 and GIP receptor agonist for obesity, being developed in both injectable and oral forms, which puts Viking among the most closely watched challengers in the booming weight-loss drug market dominated by Novo Nordisk and Eli Lilly. Viking is also developing VK2809, a thyroid-hormone receptor beta agonist for non-alcoholic steatohepatitis (NASH/MASH), and VK0214 for a rare disease (X-linked adrenoleukodystrophy). As a clinical-stage company, Viking has no approved products and generates essentially no product revenue, funding itself from cash on its balance sheet. Headquartered in San Diego, California, VKTX is a speculative, binary biotech whose value hinges on clinical-trial outcomes and the eventual commercial path for its lead obesity drug.

Full VKTX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• LIND drivers: Occupancy and pricing on a fixed fleet; Land Experiences as a second engine.
• VKTX drivers: Lead obesity program (VK2735); Pipeline breadth in metabolic disease.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Lindblad sells expensive discretionary trips, so a recession, a stock market drawdown among affluent travelers, or a shock like the 2020 pandemic shutdown can empty ships quickly while debt and vessel costs stay fixed. For VKTX, viking is a clinical-stage biotech with no approved products and essentially no product revenue, so it is highly speculative and potentially binary.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick LIND if you believe its drivers more; VKTX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LIND and VKTX guides.

LIND. Earnings multiples are distorted because interest, depreciation on the fleet and minority interests in the land brands still push GAAP results to around breakeven, which is why the forward P/E sits above ~60x. Enterprise value of ~$2.70 billion against ~$134 million of trailing EBITDA (~20x) and 2026 adjusted EBITDA guidance of ~$140 to $148 million is the more common frame for a leveraged travel operator. At ~2.8 times sales, the shares price in continued growth in both yield and capacity. For a base, full-year 2025 tour revenue was ~$771.0 million, up 20%, so the 2026 guidance midpoint implies roughly 12% to 13% growth on top of that, with the White Desert contribution included.

VKTX. Viking has no earnings to value on a P/E basis; the stock is priced on the probability-weighted potential of its pipeline, above all VK2735 in obesity, and on acquisition speculation. The shares are highly volatile and move sharply on trial readouts and deal rumors. Cash runway matters because additional fundraising could dilute holders. All figures are approximate and should be verified against current filings.

Headline figures (approximate, October 2026): LIND shows revenue (ttm) ~$831M, ebitda (ttm) ~$134M, net income (ttm) ~-$20M, market cap ~$2.35B; VKTX shows business stage Clinical-stage biotech, no approved products, lead program VK2735 (dual GLP-1/GIP agonist) for obesity, injectable + oral, other programs VK2809 (NASH/MASH), VK0214 (rare disease), product revenue ~$0 (no approved products).

LIND and VKTX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LIND and VKTX exposure against your real portfolio. It is not an investment adviser.